APA (7th ed.) Citation

LV, R., Z, B., AM, B., I, M., R, O., M, L., . . . SA, W. (2025). Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer. Breast cancer research : BCR, 27(1), 146. https://doi.org/10.1186/s13058-025-02095-6

Chicago Style (17th ed.) Citation

LV, Ravani, Bagheri Z, Brufsky AM, Michelon I, O'Regan R, Lustberg M, Han H, Wang M, and Wander SA. "Comparative Efficacy of First- Versus Second-line CDK4/6 Inhibition in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer." Breast Cancer Research : BCR 27, no. 1 (2025): 146. https://doi.org/10.1186/s13058-025-02095-6.

MLA (9th ed.) Citation

LV, Ravani, et al. "Comparative Efficacy of First- Versus Second-line CDK4/6 Inhibition in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer." Breast Cancer Research : BCR, vol. 27, no. 1, 2025, p. 146, https://doi.org/10.1186/s13058-025-02095-6.